Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Average Target Price from Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given an average recommendation of “Buy” by the ten analysts that are covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.31.

A number of equities analysts recently weighed in on TRVI shares. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, December 12th. HC Wainwright boosted their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, B. Riley restated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $67,000. SG Americas Securities LLC raised its holdings in shares of Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock valued at $110,000 after purchasing an additional 3,387 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Trevi Therapeutics by 220.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares during the last quarter. Barclays PLC grew its stake in shares of Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after purchasing an additional 61,317 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Up 1.0 %

Shares of NASDAQ TRVI opened at $3.94 on Monday. Trevi Therapeutics has a 12-month low of $1.35 and a 12-month high of $4.68. The stock has a market cap of $302.87 million, a PE ratio of -8.95 and a beta of 0.87. The company has a 50-day moving average of $3.69 and a 200 day moving average of $3.26.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the firm earned ($0.08) EPS. On average, sell-side analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.